BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Steylen PM, van der Heijden FM, Kok HD, Sijben NA, Verhoeven WM. Cardiometabolic comorbidity in antipsychotic treated patients: need for systematic evaluation and treatment. Int J Psychiatry Clin Pract. 2013;17:125-130. [PMID: 23437800 DOI: 10.3109/13651501.2013.779000] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Habtewold TD, Islam MA, Liemburg EJ, Bruggeman R, Alizadeh BZ; GROUP Investigators. Polygenic risk score for schizophrenia was not associated with glycemic level (HbA1c) in patients with non-affective psychosis: Genetic Risk and Outcome of Psychosis (GROUP) cohort study. J Psychosom Res 2020;132:109968. [PMID: 32169752 DOI: 10.1016/j.jpsychores.2020.109968] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
2 Cason N, Babeş PA, Béres E, Babeş K. Assessment of Long Term Metabolic Effects of Atypical Antipsychotics in Schizophrenia Patients. Romanian Journal of Diabetes Nutrition and Metabolic Diseases 2019;26:267-77. [DOI: 10.2478/rjdnmd-2019-0028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Mamakou V, Hackinger S, Zengini E, Tsompanaki E, Marouli E, Serafetinidis I, Prins B, Karabela A, Glezou E, Southam L, Rayner NW, Kuchenbaecker K, Lamnissou K, Kontaxakis V, Dedoussis G, Gonidakis F, Thanopoulou A, Tentolouris N, Zeggini E. Combination therapy as a potential risk factor for the development of type 2 diabetes in patients with schizophrenia: the GOMAP study. BMC Psychiatry 2018;18:249. [PMID: 30071838 DOI: 10.1186/s12888-018-1826-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
4 Jeong SH, Lee NY, Kim SH, Chung IW, Youn T, Kang UG, Ahn YM, You HY, Kim YS. Long-Term Evolution of Metabolic Status in Patients with Schizophrenia Stably Maintained on Second-Generation Antipsychotics. Psychiatry Investig 2018;15:628-37. [PMID: 29940717 DOI: 10.30773/pi.2018.01.18.1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
5 Blomqvist M, Ivarsson A, Carlsson IM, Sandgren A, Jormfeldt H. Health Risks among People with Severe Mental Illness in Psychiatric Outpatient Settings. Issues Ment Health Nurs 2018;39:585-91. [PMID: 29446657 DOI: 10.1080/01612840.2017.1422200] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
6 Sjo CP, Stenstrøm AD, Bojesen AB, Frølich JS, Bilenberg N. Development of Metabolic Syndrome in Drug-Naive Adolescents After 12 Months of Second-Generation Antipsychotic Treatment. Journal of Child and Adolescent Psychopharmacology 2017;27:884-91. [DOI: 10.1089/cap.2016.0171] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
7 Buijs FN, León-Mercado L, Guzmán-Ruiz M, Guerrero-Vargas NN, Romo-Nava F, Buijs RM. The Circadian System: A Regulatory Feedback Network of Periphery and Brain. Physiology (Bethesda) 2016;31:170-81. [PMID: 27053731 DOI: 10.1152/physiol.00037.2015] [Cited by in Crossref: 76] [Cited by in F6Publishing: 86] [Article Influence: 12.7] [Reference Citation Analysis]
8 Ward M, Druss B. The epidemiology of diabetes in psychotic disorders. The Lancet Psychiatry 2015;2:431-51. [DOI: 10.1016/s2215-0366(15)00007-3] [Cited by in Crossref: 75] [Cited by in F6Publishing: 81] [Article Influence: 9.4] [Reference Citation Analysis]
9 Sicras-Mainar A, Maurino J, Ruiz-Beato E, Navarro-Artieda R. Prevalence of metabolic syndrome according to the presence of negative symptoms in patients with schizophrenia. Neuropsychiatr Dis Treat 2015;11:51-7. [PMID: 25565850 DOI: 10.2147/NDT.S75449] [Cited by in Crossref: 7] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
10 Happell B, Platania-phung C, Stanton R, Millar F. Exploring the Views of Nurses on the Cardiometabolic Health Nurse in Mental Health Services in Australia. Issues in Mental Health Nursing 2015;36:135-44. [DOI: 10.3109/01612840.2014.901449] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
11 Happell B, Stanton R, Platania-phung C, Mckenna B, Scott D. The Cardiometabolic Health Nurse: Physical Health Behaviour Outcomes from a Randomised Controlled Trial. Issues in Mental Health Nursing 2014;35:768-75. [DOI: 10.3109/01612840.2014.896061] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
12 Richly P, López P, Gleichgerrcht E, Flichtentrei D, Prats M, Mastandueno R, Bustin J, Cetkovich-Bakmas M. Psychiatrists’ approach to vascular risk assessment in Latin America. World J Psychiatr 2014; 4(3): 56-61 [PMID: 25250222 DOI: 10.5498/wjp.v4.i3.56] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
13 Millar F, Sands N, Elsom S. Factors influencing cardiometabolic monitoring practices in an adult community mental health service: Cardiometabolic Monitoring Practices. Int J Ment Health Nurs 2014;23:479-89. [DOI: 10.1111/inm.12085] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]